Congestive heart failure cardiac catheterization: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (8 intermediate revisions by the same user not shown) | |||
| Line 31: | Line 31: | ||
*[[Computed tomography coronary angiography]] ([[CTCA]]) may be considered in [[patients]] with a low to intermediate pre-test probability of[[CAD]], or equivocal result of non-invasive [[stress tests]] in order to exclude the diagnosis of [[CAD]].<ref name="pmid31504439">{{cite journal |vauthors=Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ |title=2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes |journal=Eur Heart J |volume=41 |issue=3 |pages=407–477 |date=January 2020 |pmid=31504439 |doi=10.1093/eurheartj/ehz425 |url=}}</ref> | *[[Computed tomography coronary angiography]] ([[CTCA]]) may be considered in [[patients]] with a low to intermediate pre-test probability of[[CAD]], or equivocal result of non-invasive [[stress tests]] in order to exclude the diagnosis of [[CAD]].<ref name="pmid31504439">{{cite journal |vauthors=Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ |title=2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes |journal=Eur Heart J |volume=41 |issue=3 |pages=407–477 |date=January 2020 |pmid=31504439 |doi=10.1093/eurheartj/ehz425 |url=}}</ref> | ||
== | ==2021 European Society of Cardiology (DO NOT EDIT) <ref name="pmid34447992">{{cite journal |vauthors=McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A |title=2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure |journal=Eur Heart J |volume=42 |issue=36 |pages=3599–3726 |date=September 2021 |pmid=34447992 |doi=10.1093/eurheartj/ehab368 |url=}}</ref>== | ||
===[[Coronary Angiography]]=== | |||
{|class="wikitable" style="width:80%" | {|class="wikitable" style="width:80%" | ||
| Line 57: | Line 59: | ||
|} | |} | ||
=== | ===[[Coronary CT Angiography]] === | ||
{|class="wikitable" style="width:80%" | {|class="wikitable" style="width:80%" | ||
| Line 75: | Line 77: | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>[[Endomyocardial biopsy]] should be considered in [[patients]] with rapidly progressive [[HF]] despite standard therapy when there is a probability of a specific diagnosis, which can be confirmed only in [[myocardial]] samples.([[ESC guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki> | | bgcolor="LightGreen"|<nowiki>"</nowiki>[[Endomyocardial biopsy]] should be considered in [[patients]] with rapidly progressive [[HF]] despite standard therapy when there is a probability of a specific diagnosis, which can be confirmed only in [[myocardial]] samples.([[ESC guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki> | ||
|- | |- | ||
|} | |||
===Genetic Evaluation and Testing 2022 AHA/ACC/HFSA Heart Failure Guideline (DO NOT EDIT) <ref name="pmid35363500">{{cite journal| author=Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM | display-authors=etal| title=2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2022 | volume= 145 | issue= 18 | pages= e876-e894 | pmid=35363500 | doi=10.1161/CIR.0000000000001062 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=35363500 }} </ref> === | |||
{|class="wikitable" style="width:80%" | |||
|- | |||
|colspan="1" style="text-align:center; background:LightGreen"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | |||
|- | |||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' In first-degree relatives of selected [[patients]] with [[genetic]] or [[inherited]] [[cardiomyopathies]], [[genetic screening]] and counseling are recommended to detect [[cardiac disease]] and prompt consideration of [[treatments]] to decrease [[HF]] progression and sudden [[death]]. <ref name="pmid32624524">{{cite journal| author=Marume K, Noguchi T, Tateishi E, Morita Y, Miura H, Nishimura K | display-authors=etal| title=Prognosis and Clinical Characteristics of Dilated Cardiomyopathy With Family History via Pedigree Analysis. | journal=Circ J | year= 2020 | volume= 84 | issue= 8 | pages= 1284-1293 | pmid=32624524 | doi=10.1253/circj.CJ-19-1176 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32624524 }} </ref><ref name="pmid26925241">{{cite journal| author=Waddell-Smith KE, Donoghue T, Oates S, Graham A, Crawford J, Stiles MK | display-authors=etal| title=Inpatient detection of cardiac-inherited disease: the impact of improving family history taking. | journal=Open Heart | year= 2016 | volume= 3 | issue= 1 | pages= e000329 | pmid=26925241 | doi=10.1136/openhrt-2015-000329 | pmc=4762189 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26925241 }} </ref> ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B-NR]])'' <nowiki>"</nowiki> | |||
|} | |||
{|class="wikitable" style="width:80%" | |||
|- | |||
|colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] | |||
|- | |||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' In select [[patients]] with [[nonischemic cardiomyopathy]], referral for [[genetic counseling]] and testing is reasonable to identify conditions that could guide [[treatment]] for [[patients]] and [[family]] members.<ref name="pmid24503780">{{cite journal| author=Pugh TJ, Kelly MA, Gowrisankar S, Hynes E, Seidman MA, Baxter SM | display-authors=etal| title=The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing. | journal=Genet Med | year= 2014 | volume= 16 | issue= 8 | pages= 601-8 | pmid=24503780 | doi=10.1038/gim.2013.204 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24503780 }} </ref><ref name="pmid25163546">{{cite journal| author=Haas J, Frese KS, Peil B, Kloos W, Keller A, Nietsch R | display-authors=etal| title=Atlas of the clinical genetics of human dilated cardiomyopathy. | journal=Eur Heart J | year= 2015 | volume= 36 | issue= 18 | pages= 1123-35a | pmid=25163546 | doi=10.1093/eurheartj/ehu301 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25163546 }} </ref> ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B-NR]])'' <nowiki>"</nowiki> | |||
|} | |} | ||
Latest revision as of 23:08, 22 June 2022
 |
Resident Survival Guide |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Sara Zand, M.D.[2] Lakshmi Gopalakrishnan, M.B.B.S. [3] Edzel Lorraine Co, DMD, MD[4]
Overview
Coronary angiography is recommended in patients with heart failure, who have angina pectoris or an angina equivalent despite pharmacological therapy, in order to establish the diagnosis of CAD and its severity. Coronary angiography may also be considered in patients with HFrEF who have an intermediate to high pre-test probability of CAD and who are considered potentially suitable for coronary revascularization.
Cardiac Catheterization
Coronary Angiography
- Invasive coronary angiography is useful to rule out significant CAD in patients with cardiac dysfunction.
- It is recommended in patients with angina despite pharmacological therapy or symptomatic ventricular arrhythmias.
- In patients with HFrEF with an intermediate to high pre-test probability of CAD and the presence of ischaemia in noninvasive stress tests, invasive coronary angiography may be considered.
Hemodynamic Assessment
Right Heart Catheterization
Right heart catheterization can be useful to assess the following:
- Pulmonary capillary wedge pressure
- Pulmonary artery pressure to diagnose pulmonary hypertension and respond to therapy
- Right heart catheterization should be considered in patients where HF is thought to be due to constrictive pericarditis, restrictive cardiomyopathy, congenital heart disease, and high output states.
Computed tomography coronary angiography (CTCA)
- Computed tomography coronary angiography (CTCA) may be considered in patients with a low to intermediate pre-test probability ofCAD, or equivocal result of non-invasive stress tests in order to exclude the diagnosis of CAD.[1]
2021 European Society of Cardiology (DO NOT EDIT) [2]
Coronary Angiography
| Class I |
| "Invasive coronary angiography is recommended in patients with angina despite medical therapy or symptomatic ventricular arrhythmias.(Level of Evidence: B) " |
| Class IIb |
| " Invasive coronary angiography may be considered in patients with HFrEF with an intermediate to high pre-test probability of CAD and the presence of ischemia in non-invasive stress tests.(Level of Evidence: B) " |
| Class I |
| " Right heart catheterization is recommended in patients with severe HF being evaluated for heart transplantation or mechanical circulatory support (Level of Evidence: C) " |
| Class IIa |
| " Right heart catheterization is reasonable in HF patients with suspicion of constrictive pericarditis, restrictive cardiomyopathy, congenital heart disease, and high output states.(Level of Evidence: C) " |
| Class IIb |
| " Right heart catheterization may be considered in selected patients with HFpEF to confirm the diagnosis..(Level of Evidence: C) " |
Coronary CT Angiography
| Class IIa |
| "Coronary CT angiography should be considered in patients with a low to intermediate pre-test probability of CAD or those with equivocal non-invasive stress tests in order to rule out coronary artery stenosis.(Level of Evidence: C) " |
| Class IIa |
| "Endomyocardial biopsy should be considered in patients with rapidly progressive HF despite standard therapy when there is a probability of a specific diagnosis, which can be confirmed only in myocardial samples.(Level of Evidence: C) " |
Genetic Evaluation and Testing 2022 AHA/ACC/HFSA Heart Failure Guideline (DO NOT EDIT) [3]
| Class I |
| "1. In first-degree relatives of selected patients with genetic or inherited cardiomyopathies, genetic screening and counseling are recommended to detect cardiac disease and prompt consideration of treatments to decrease HF progression and sudden death. [4][5] (Level of Evidence: B-NR) " |
| Class IIa |
| "1. In select patients with nonischemic cardiomyopathy, referral for genetic counseling and testing is reasonable to identify conditions that could guide treatment for patients and family members.[6][7] (Level of Evidence: B-NR) " |
References
- ↑ Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ (January 2020). "2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes". Eur Heart J. 41 (3): 407–477. doi:10.1093/eurheartj/ehz425. PMID 31504439.
- ↑ McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland J, Coats A, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam C, Lyon AR, McMurray J, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano G, Ruschitzka F, Kathrine Skibelund A (September 2021). "2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure". Eur Heart J. 42 (36): 3599–3726. doi:10.1093/eurheartj/ehab368. PMID 34447992 Check
|pmid=value (help). Vancouver style error: initials (help) - ↑ Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM; et al. (2022). "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". Circulation. 145 (18): e876–e894. doi:10.1161/CIR.0000000000001062. PMID 35363500 Check
|pmid=value (help). - ↑ Marume K, Noguchi T, Tateishi E, Morita Y, Miura H, Nishimura K; et al. (2020). "Prognosis and Clinical Characteristics of Dilated Cardiomyopathy With Family History via Pedigree Analysis". Circ J. 84 (8): 1284–1293. doi:10.1253/circj.CJ-19-1176. PMID 32624524 Check
|pmid=value (help). - ↑ Waddell-Smith KE, Donoghue T, Oates S, Graham A, Crawford J, Stiles MK; et al. (2016). "Inpatient detection of cardiac-inherited disease: the impact of improving family history taking". Open Heart. 3 (1): e000329. doi:10.1136/openhrt-2015-000329. PMC 4762189. PMID 26925241.
- ↑ Pugh TJ, Kelly MA, Gowrisankar S, Hynes E, Seidman MA, Baxter SM; et al. (2014). "The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing". Genet Med. 16 (8): 601–8. doi:10.1038/gim.2013.204. PMID 24503780.
- ↑ Haas J, Frese KS, Peil B, Kloos W, Keller A, Nietsch R; et al. (2015). "Atlas of the clinical genetics of human dilated cardiomyopathy". Eur Heart J. 36 (18): 1123–35a. doi:10.1093/eurheartj/ehu301. PMID 25163546.